Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;24(7):889-904.
doi: 10.1007/s11912-021-01163-2. Epub 2022 Mar 26.

Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers

Juliet E Wolford  1 , Erin Ferrigni  1 , Daniel Margul  1 , Thomas J Herzog  2   3
Affiliations
Review

Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers

Juliet E Wolford et al. Curr Oncol Rep. 2022 Jul.

Abstract

Purpose of review: The treatment of patients with advanced gynecologic malignancies remains challenging. Advancements in genomics have led to recognition and development of individualized therapeutic targets. This article reviews the current trends in precision medicine for treatment of gynecologic cancers.

Recent findings: With the identification of the molecular aberrations inherent to gynecologic malignancies, we have discovered targetable mutations. Specific to ovarian, endometrial and cervical cancers, potential therapeutic targets that have been identified and shown to have benefit include: hormonal therapies, anti-angiogenic agents, poly-ADP-ribose polymerase inhibitors (PARPi), and immunotherapy. The adoption of targeted therapeutics for the treatment of gynecologic cancers has been gradual, but we have started to see the rapid employment of novel targeted agents into clinical trial development, leading to new treatment approvals. However, there are challenges to the universal precision medicine implementation, and future studies need to identify, discover, and validate robust biomarkers with strong prognostic/predictive capabilities.

Keywords: Cervical cancer; Endometrial cancer; Gynecologic cancers; Ovarian cancer; Personalized medicine; Precision medicine.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Deavers MT, Malpica A, Silva EG. Immunohistochemistry in gynecological pathology. Int J Gynecol Cancer. 2003;13(5):567–79. https://doi.org/10.1046/j.1525-1438.2003.13387.x . - DOI - PubMed
    1. Kaspar HG, Crum CP. The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders. Arch Pathol Lab Med. 2015;139(1):39–54. https://doi.org/10.5858/arpa.2014-0057-RA . - DOI - PubMed
    1. Kalampokas E, Payne F, Gurumurthy M. An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology. Gynecol Oncol Published online. 2018. https://doi.org/10.1016/j.ygyno.2018.05.023 . - DOI
    1. Peiro G, Mayr D, Hillemanns P, Lohrs U, Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol. 2004;17(3):227–87. https://doi.org/10.1038/modpathol.3800006 . - DOI - PubMed
    1. Huang NF, Gupta M, Varghese S, Rao S, Luke S. Detection of numerical chromosomal abnormalities in epithelial ovarian neoplasms by fluorescence in situ hybridization (FISH) and a review of the current literature. Appl Immunohistochem Mol Morphol. 2002;10(2):187–93. https://doi.org/10.1097/00129039-200206000-00016 . - DOI - PubMed

MeSH terms

Substances